Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 4/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036249 | 0.89 | GCGR (0.35) | GCGGCGRS100A4FABP3FABP4 | |
| SCHEMBL6035302 | 0.89 | PPARD (0.36) | GCGGCGRS100A4FABP3FABP4 | |
| SCHEMBL6035374 | 0.88 | GCGR (0.37) | GCGGCGRS100A4FABP3FABP4 | |
| SCHEMBL6036397 | 0.86 | GCGR (0.36) | GCGMLYCDGCGRHRH3CNR2 | |
| SCHEMBL6036403 | 0.86 | GCGR (0.36) | GCGMLYCDGCGRL3MBTL1HRH3 | |
| SCHEMBL6035849 | 0.84 | MLYCD (0.36) | GCGMLYCDGCGRL3MBTL1FABP3 | |
| SCHEMBL6036332 | 0.84 | GCGR (0.36) | GCGMLYCDGCGRHRH3CNR2 | |
| SCHEMBL6036236 | 0.82 | MLYCD (0.35) | GCGMLYCDGCGRL3MBTL1FABP3 | |
| SCHEMBL6034569 | 0.80 | PPARD (0.35) | GCGL3MBTL1HRH3ACACBS100A4 | |
| SCHEMBL6035279 | 0.79 | GCGR (0.37) | GCGMLYCDGCGRHRH3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | GCG 284/4885MLYCD 962/4885GCGR 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.